Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Characterization of a new Leishmania major strain for use in a controlled human infection model

H. Ashwin, J. Sadlova, B. Vojtkova, T. Becvar, P. Lypaczewski, E. Schwartz, E. Greensted, K. Van Bocxlaer, M. Pasin, KS. Lipinski, V. Parkash, G. Matlashewski, AM. Layton, CJ. Lacey, CL. Jaffe, P. Volf, PM. Kaye

. 2021 ; 12 (1) : 215. [pub] 20210111

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21011613

Grantová podpora
MR/R014973/1 Medical Research Council - United Kingdom
MR/R014973 Medical Research Council - United Kingdom

Leishmaniasis is widely regarded as a vaccine-preventable disease, but the costs required to reach pivotal Phase 3 studies and uncertainty about which candidate vaccines should be progressed into human studies significantly limits progress in vaccine development for this neglected tropical disease. Controlled human infection models (CHIMs) provide a pathway for accelerating vaccine development and to more fully understand disease pathogenesis and correlates of protection. Here, we describe the isolation, characterization and GMP manufacture of a new clinical strain of Leishmania major. Two fresh strains of L. major from Israel were initially compared by genome sequencing, in vivo infectivity and drug sensitivity in mice, and development and transmission competence in sand flies, allowing one to be selected for GMP production. This study addresses a major roadblock in the development of vaccines for leishmaniasis, providing a key resource for CHIM studies of sand fly transmitted cutaneous leishmaniasis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21011613
003      
CZ-PrNML
005      
20210507103752.0
007      
ta
008      
210420s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41467-020-20569-3 $2 doi
035    __
$a (PubMed)33431825
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Ashwin, Helen $u York Biomedical Research Institute, Hull York Medical School, University of York, York, UK
245    10
$a Characterization of a new Leishmania major strain for use in a controlled human infection model / $c H. Ashwin, J. Sadlova, B. Vojtkova, T. Becvar, P. Lypaczewski, E. Schwartz, E. Greensted, K. Van Bocxlaer, M. Pasin, KS. Lipinski, V. Parkash, G. Matlashewski, AM. Layton, CJ. Lacey, CL. Jaffe, P. Volf, PM. Kaye
520    9_
$a Leishmaniasis is widely regarded as a vaccine-preventable disease, but the costs required to reach pivotal Phase 3 studies and uncertainty about which candidate vaccines should be progressed into human studies significantly limits progress in vaccine development for this neglected tropical disease. Controlled human infection models (CHIMs) provide a pathway for accelerating vaccine development and to more fully understand disease pathogenesis and correlates of protection. Here, we describe the isolation, characterization and GMP manufacture of a new clinical strain of Leishmania major. Two fresh strains of L. major from Israel were initially compared by genome sequencing, in vivo infectivity and drug sensitivity in mice, and development and transmission competence in sand flies, allowing one to be selected for GMP production. This study addresses a major roadblock in the development of vaccines for leishmaniasis, providing a key resource for CHIM studies of sand fly transmitted cutaneous leishmaniasis.
650    _2
$a zvířata $7 D000818
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a lidé $7 D006801
650    _2
$a hmyz - vektory $x parazitologie $7 D007303
650    _2
$a Leishmania major $x genetika $x růst a vývoj $x fyziologie $7 D018320
650    _2
$a leishmanióza kožní $x parazitologie $x přenos $7 D016773
650    _2
$a myši inbrední BALB C $7 D008807
650    _2
$a paraziti $x genetika $7 D010271
650    _2
$a fylogeneze $7 D010802
650    _2
$a Psychodidae $x parazitologie $7 D011576
650    _2
$a sekvenování celého genomu $7 D000073336
651    _2
$a Izrael $7 D007557
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sadlova, Jovana $u Department of Parasitology, Faculty of Science, Charles University, Viničná 7, Prague, Czech Republic
700    1_
$a Vojtkova, Barbora $u Department of Parasitology, Faculty of Science, Charles University, Viničná 7, Prague, Czech Republic
700    1_
$a Becvar, Tomas $u Department of Parasitology, Faculty of Science, Charles University, Viničná 7, Prague, Czech Republic
700    1_
$a Lypaczewski, Patrick $u Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada
700    1_
$a Schwartz, Eli $u The Center for Geographic Medicine and Tropical Diseases, Chaim Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
700    1_
$a Greensted, Elizabeth $u York Biomedical Research Institute, Hull York Medical School, University of York, York, UK
700    1_
$a Van Bocxlaer, Katrien $u York Biomedical Research Institute, Hull York Medical School, University of York, York, UK
700    1_
$a Pasin, Marion $u Vibalogics GmbH, Cuxhaven, Germany
700    1_
$a Lipinski, Kai S $u Vibalogics GmbH, Cuxhaven, Germany
700    1_
$a Parkash, Vivak $u York Biomedical Research Institute, Hull York Medical School, University of York, York, UK
700    1_
$a Matlashewski, Greg $u Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada
700    1_
$a Layton, Alison M $u York Biomedical Research Institute, Hull York Medical School, University of York, York, UK
700    1_
$a Lacey, Charles J $u York Biomedical Research Institute, Hull York Medical School, University of York, York, UK
700    1_
$a Jaffe, Charles L $u The Hebrew University-Hadassah Medical School, Jerusalem, Israel. cjaffe@mail.huji.ac.il
700    1_
$a Volf, Petr $u Department of Parasitology, Faculty of Science, Charles University, Viničná 7, Prague, Czech Republic. volf@cesnet.cz
700    1_
$a Kaye, Paul M $u York Biomedical Research Institute, Hull York Medical School, University of York, York, UK. paul.kaye@york.ac.uk
773    0_
$w MED00184850 $t Nature communications $x 2041-1723 $g Roč. 12, č. 1 (2021), s. 215
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33431825 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507103751 $b ABA008
999    __
$a ok $b bmc $g 1650087 $s 1131992
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 12 $c 1 $d 215 $e 20210111 $i 2041-1723 $m Nature communications $n Nat Commun $x MED00184850
GRA    __
$a MR/R014973/1 $p Medical Research Council $2 United Kingdom
GRA    __
$a MR/R014973 $p Medical Research Council $2 United Kingdom
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace